Analyst Expectations for Alnylam Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 20 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. The average price target is $261.95, implying an upside from the current price of $177.1. This represents a 10.06% decrease from the previous average price target of $291.25.
September 29, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have given an average price target of $261.95 for Alnylam Pharmaceuticals, implying an upside from the current price.
The average price target given by analysts suggests a potential upside for Alnylam Pharmaceuticals. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100